Combined ursodeoxycholic acid (<scp>UDCA</scp>) and fenofibrate in primary biliary cholangitis patients with incomplete<scp>UDCA</scp>response may improve outcomes

Abstract

Fenofibrate therapy is associated with significant improvement in alkaline phosphatase, decompensation-free and transplant-free survival in PBC patients with incomplete UDCA response. However, fenofibrate should be used cautiously in cirrhosis, with close monitoring for clinical/biochemical decompensation. Additional studies are required to assess the validity of alkaline phosphatase as an appropriate response criteria for fibrate therapy.